Immunotherapeutic Approaches for Alzheimer's Disease

Neuron

Volumn 85, Issue 6, 2015, Pages 1162-1176

  Wisniewski, Thomas ^a   Goñi, Fernando ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; CRENEZUMAB; FREUND ADJUVANT; GAMMA INTERFERON; GANTENERUMAB; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NOOTROPIC AGENT; PLACEBO; PRESENILIN 1; PRESENILIN 2; SOLANEUZUMAB; TAU ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; VANUTIDE CRIDIFICAR; ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLEEDING; CLINICAL TRIAL (TOPIC); CONFORMATIONAL TRANSITION; CONFUSION; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; EDEMA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HEADACHE; HEMOSIDEROSIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MENINGITIS; MENINGOENCEPHALITIS; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MOUSE; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SYNTHESIS; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; VASOGENIC EDEMA; ANIMAL; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; TAU PROTEINS;

EID: 84925279976     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.12.064     Document Type: Review

References (151)

1. Adolfsson O., Pihlgren M., Toni N., Varisco Y., Buccarello A.L., Antoniello K., Lohmann S., Piorkowska K., Gafner V., Atwal J.K., et al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J.Neurosci. 2012, 32:9677-9689.
2. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
3. Ashe K.H., Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 2013, 7:55-59.
4. Asuni A.A., Boutajangout A., Scholtzova H., Knudsen E., Li Y., Quartermain D., Frangione B., Wisniewski T., Sigurdsson E.M. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur. J. Neurosci. 2006, 24:2530-2542.
5. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J.Neurosci. 2007, 27:9115-9129.
6. Bancher C., Braak H., Fischer P., Jellinger K.A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett. 1993, 162:179-182.
7. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
8. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA 2003, 100:2023-2028.
9. Barry A.E., Klyubin I., Mc Donald J.M., Mably A.J., Farrell M.A., Scott M., Walsh D.M., Rowan M.J. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP invivo is prevented by immunotargeting cellular prion protein. J.Neurosci. 2011, 31:7259-7263.
10. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64:94-101.
11. Bertram L., Tanzi R.E. The genetics of Alzheimer's disease. Prog. Mol. Biol. Transl. Sci. 2012, 107:79-100.
12. Beydoun M.A., Beydoun H.A., Gamaldo A.A., Teel A., Zonderman A.B., Wang Y. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health 2014, 14:643.
13. Blurton-Jones M., Laferla F.M. Pathways by which Abeta facilitates tau pathology. Curr. Alzheimer Res. 2006, 3:437-448.
14. Boche D., Nicoll J.A. The role of the immune system in clearance of Abeta from the brain. Brain Pathol. 2008, 18:267-278.
15. Bohrmann B., Baumann K., Benz J., Gerber F., Huber W., Knoflach F., Messer J., Oroszlan K., Rauchenberger R., Richter W.F., et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J.Alzheimers Dis. 2012, 28:49-69.
16. Bombois S., Maurage C.A., Gompel M., Deramecourt V., Mackowiak-Cordoliani M.A., Black R.S., Lavielle R., Delacourte A., Pasquier F. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol. 2007, 64:583-587.
17. Boutajangout A., Wisniewski T. The innate immune system in Alzheimer's disease. Int. J. Cell Biol. 2013, 2013:576383.
18. Boutajangout A., Wisniewski T. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Gerontology 2014, 60:381-385.
19. Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J.Neurosci. 2010, 30:16559-16566.
20. Boutajangout A., Ingadottir J., Davies P., Sigurdsson E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J.Neurochem. 2011, 118:658-667.
21. Braak H., Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011, 121:171-181.
22. Castellani R.J., Lee H.G., Zhu X., Perry G., Smith M.A. Alzheimer disease pathology as a host response. J.Neuropathol. Exp. Neurol. 2008, 67:523-531.
23. Chai X., Wu S., Murray T.K., Kinley R., Cella C.V., Sims H., Buckner N., Hanmer J., Davies P., O'Neill M.J., et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J.Biol. Chem. 2011, 286:34457-34467.
24. Chung E., Ji Y., Sun Y., Kascsak R.J., Kascsak R.B., Mehta P.D., Strittmatter S.M., Wisniewski T. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease mouse model. BMC Neurosci. 2010, 11:130.
25. Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11:909-913.
26. Colby D.W., Prusiner S.B. Prions. Cold Spring Harb. Perspect. Biol. 2011, 3:a006833.
27. Congdon E.E., Gu J., Sait H.B., Sigurdsson E.M. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J.Biol. Chem. 2013, 288:35452-35465.
28. Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Arnold S.E., Attems J., Beach T.G., Bigio E.H., et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014, 128:755-766.
29. d'Abramo C., Acker C.M., Jimenez H.T., Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 2013, 8:e62402.
30. D'Andrea M.R., Nagele R.G., Wang H.Y., Peterson P.A., Lee D.H. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 2001, 38:120-134.
31. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001, 98:8850-8855.
32. DeMattos R.B., Lu J., Tang Y., Racke M.M., Delong C.A., Tzaferis J.A., Hole J.T., Forster B.M., McDonnell P.C., Liu F., et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 2012, 76:908-920.
33. Di Marco L.Y., Marzo A., Muñoz-Ruiz M., Ikram M.A., Kivipelto M., Ruefenacht D., Venneri A., Soininen H., Wanke I., Ventikos Y.A., Frangi A.F. Modifiable lifestyle factors in dementia: a systematic review of longitudinal observational cohort studies. J.Alzheimers Dis. 2014, 42:119-135.
34. Dodel R., Rominger A., Bartenstein P., Barkhof F., Blennow K., Förster S., Winter Y., Bach J.P., Popp J., Alferink J., et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013, 12:233-243.
35. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., Raman R., Sun X., Aisen P.S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N.Engl. J. Med. 2014, 370:311-321. Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study GroupSolanezumab Study Group.
36. Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol. 2011, 121:145-147.
37. Eidenmüller J., Fath T., Maas T., Pool M., Sontag E., Brandt R. Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochem. J. 2001, 357:759-767.
38. Elobeid A., Soininen H., Alafuzoff I. Hyperphosphorylated tau in young and middle-aged subjects. Acta Neuropathol. 2012, 123:97-104.
39. Farlow M.R., Brosch J.R. Immunotherapy for Alzheimer's disease. Neurol. Clin. 2013, 31:869-878.
40. Farlow M., Arnold S.E., van Dyck C.H., Aisen P.S., Snider B.J., Porsteinsson A.P., Friedrich S., Dean R.A., Gonzales C., Sethuraman G., et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012, 8:261-271.
41. Fath T., Eidenmüller J., Brandt R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J.Neurosci. 2002, 22:9733-9741.
42. Ferrer I., Boada Rovira M., Sánchez Guerra M.L., Rey M.J., Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11-20.
43. Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., Patel A., Lossinsky A.S., Graves M.C., Gustavson A., Sayre J., et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J.Alzheimers Dis. 2005, 7:221-232.
44. Fillit H., Hess G., Hill J., Bonnet P., Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009, 73:180-185.
45. Frackowiak J., Wisniewski H.M., Wegiel J., Merz G.S., Iqbal K., Wang K.C. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. 1992, 84:225-233.
46. Frost J.L., Le K.X., Cynis H., Ekpo E., Kleinschmidt M., Palmour R.M., Ervin F.R., Snigdha S., Cotman C.W., Saido T.C., et al. Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am. J. Pathol. 2013, 183:369-381.
47. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562. AN1792(QS-21)-201 Study Team.
48. Giuffrida M.L., Caraci F., Pignataro B., Cataldo S., De Bona P., Bruno V., Molinaro G., Pappalardo G., Messina A., Palmigiano A., et al. Beta-amyloid monomers are neuroprotective. J.Neurosci. 2009, 29:10582-10587.
49. Goñi F., Prelli F., Ji Y., Scholtzova H., Yang J., Sun Y., Liang F.X., Kascsak R., Kascsak R., Mehta P., Wisniewski T. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS ONE 2010, 5:e13391.
50. Goñi F., Herline K., Peyser D., Wong K., Ji Y., Sun Y., Mehta P., Wisniewski T. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. J.Neuroinflammation 2013, 10:150.
51. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
52. Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156:15-20.
53. Guerreiro R., Hardy J. Genetics of Alzheimer's disease. Neurotherapeutics 2014, 11:732-737.
54. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13.
55. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
56. Hartley D., Blumenthal T., Carrillo M., DiPaolo G., Esralew L., Gardiner K., Granholm A.C., Iqbal K., Krams M., Lemere C., et al. Down syndrome and Alzheimer's disease: common pathways, common goals. Alzheimers Dement. 2014, Published online December 12, 2014.
57. Hickman S.E., El Khoury J. TREM2 and the neuroimmunology of Alzheimer's disease. Biochem. Pharmacol. 2014, 88:495-498.
58. Hickman D.T., López-Deber M.P., Ndao D.M., Silva A.B., Nand D., Pihlgren M., Giriens V., Madani R., St-Pierre A., Karastaneva H., et al. Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J.Biol. Chem. 2011, 286:13966-13976.
59. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., Davey G., Moritz E., Nitsch R.M. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 2002, 8:1270-1275.
60. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38:547-554.
61. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
62. Holtzman D.M., Mandelkow E., Selkoe D.J. Alzheimer disease in 2020. Cold Spring Harb. Perspect. Med. 2012, 2:a011585.
63. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
64. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
65. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., et al. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
66. Jin J.J., Kim H.D., Maxwell J.A., Li L., Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J.Neuroinflammation 2008, 5:23.
67. Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
68. Jucker M., Walker L.C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 2011, 70:532-540.
69. Kanekiyo T., Xu H., Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?. Neuron 2014, 81:740-754.
70. Karch C.M., Cruchaga C., Goate A.M. Alzheimer's disease genetics: from the bench to the clinic. Neuron 2014, 83:11-26.
71. Kayed R., Jackson G.R. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr. Opin. Immunol. 2009, 21:359-363.
72. Kim D.H., Yeo S.H., Park J.M., Choi J.Y., Lee T.H., Park S.Y., Ock M.S., Eo J., Kim H.S., Cha H.J. Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene 2014, 545:185-193.
73. Lai A.Y., McLaurin J. Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where. Future Neurol. 2012, 7:165-176.
74. Lambert M.P., Velasco P.T., Chang L., Viola K.L., Fernandez S., Lacor P.N., Khuon D., Gong Y., Bigio E.H., Shaw P., et al. Monoclonal antibodies that target pathological assemblies of Abeta. J.Neurochem. 2007, 100:23-35.
75. Lambert M.P., Velasco P.T., Viola K.L., Klein W.L. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol. Disord. Drug Targets 2009, 8:65-81.
76. Lampron A., Elali A., Rivest S. Innate immunity in the CNS: redefining the relationship between the CNS and Its environment. Neuron 2013, 78:214-232.
77. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J.Biol. Chem. 2006, 281:4292-4299.
78. Lee D.C., Rizer J., Hunt J.B., Selenica M.L., Gordon M.N., Morgan D. Review: experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology. Neuropathol. Appl. Neurobiol. 2013, 39:69-85.
79. Lemere C.A. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol. Neurodegener. 2013, 8:36.
80. Lemere C.A., Maron R., Selkoe D.J., Weiner H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 2001, 20:705-711.
81. Majumdar A., Cruz D., Asamoah N., Buxbaum A., Sohar I., Lobel P., Maxfield F.R. Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol. Biol. Cell 2007, 18:1490-1496.
82. Maloney J.A., Bainbridge T., Gustafson A., Zhang S., Kyauk R., Steiner P., van der Brug M., Liu Y., Ernst J.A., Watts R.J., Atwal J.K. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. J.Biol. Chem. 2014, 289:30990-31000.
83. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C.G., Cribbs D.H., Agadjanyan M.G. Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J.Biol. Chem. 2007, 282:22376-22386.
84. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
85. Masliah E., Rockenstein E., Adame A., Alford M., Crews L., Hashimoto M., Seubert P., Lee M., Goldstein J., Chilcote T., et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
86. McKee A.C., Carreras I., Hossain L., Ryu H., Klein W.L., Oddo S., LaFerla F.M., Jenkins B.G., Kowall N.W., Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008, 1207:225-236.
87. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.L., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
88. Michaud J.P., Hallé M., Lampron A., Thériault P., Préfontaine P., Filali M., Tribout-Jover P., Lanteigne A.M., Jodoin R., Cluff C., et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc. Natl. Acad. Sci. USA 2013, 110:1941-1946.
89. Moreth J., Mavoungou C., Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?. Immun. Ageing 2013, 10:18.
90. Moretto N., Bolchi A., Rivetti C., Imbimbo B.P., Villetti G., Pietrini V., Polonelli L., Del Signore S., Smith K.M., Ferrante R.J., Ottonello S. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J.Biol. Chem. 2007, 282:11436-11445.
91. Morgan D. Immunotherapy for Alzheimer's disease. J.Intern. Med. 2011, 269:54-63.
92. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., et al. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
93. Muhs A., Hickman D.T., Pihlgren M., Chuard N., Giriens V., Meerschman C., van der Auwera I., van Leuven F., Sugawara M., Weingertner M.C., et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc. Natl. Acad. Sci. USA 2007, 104:9810-9815.
94. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
95. Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J.Neuropathol. Exp. Neurol. 2012, 71:362-381.
96. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448-452.
97. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., Vlachouli C., Wilkinson D., Bayer A., Games D., et al. Abeta species removal after abeta42 immunization. J.Neuropathol. Exp. Neurol. 2006, 65:1040-1048.
98. Noble W., Garwood C.J., Hanger D.P. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 2009, 3:78-83.
99. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
100. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., LaFerla F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an invivo model of Alzheimer disease. A link between Abeta and tau pathology. J.Biol. Chem. 2006, 281:1599-1604.
101. Ozudogru S.N., Lippa C.F. Disease modifying drugs targeting β-amyloid. Am. J. Alzheimers Dis. Other Demen. 2012, 27:296-300.
102. Panza F., Frisardi V., Solfrizzi V., Imbimbo B.P., Logroscino G., Santamato A., Greco A., Seripa D., Pilotto A. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy 2012, 4:213-238.
103. Potter H., Wisniewski T. Apolipoprotein e: essential catalyst of the Alzheimer amyloid cascade. Int. J. Alzheimers Dis. 2012, 2012:489428.
104. Pride M., Seubert P., Grundman M., Hagen M., Eldridge J., Black R.S. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener. Dis. 2008, 5:194-196.
105. Puzzo D., Privitera L., Leznik E., Fà M., Staniszewski A., Palmeri A., Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J.Neurosci. 2008, 28:14537-14545.
106. Rasool S., Martinez-Coria H., Wu J.W., LaFerla F., Glabe C.G. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. J.Neurochem. 2013, 126:473-482.
107. Reed-Geaghan E.G., Savage J.C., Hise A.G., Landreth G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar Abeta-stimulated microglial activation. J.Neurosci. 2009, 29:11982-11992.
108. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30:1728-1736.
109. Ren P.H., Lauckner J.E., Kachirskaia I., Heuser J.E., Melki R., Kopito R.R. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 2009, 11:219-225.
110. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
111. Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 2006, 63:1459-1467.
112. Rostagno A., Tomidokoro Y., Lashley T., Ng D., Plant G., Holton J., Frangione B., Revesz T., Ghiso J. Chromosome 13 dementias. Cell. Mol. Life Sci. 2005, 62:1814-1825.
113. Rozenstein-Tsalkovich L., Grigoriadis N., Lourbopoulos A., Nousiopoulou E., Kassis I., Abramsky O., Karussis D., Rosenmann H. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 2013, 248:451-456.
114. Ryan J.M., Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J.Alzheimers Dis. 2009, 17:243.
115. Sadowski M., Wisniewski T. Disease modifying approaches for Alzheimer's pathology. Curr. Pharm. Des. 2007, 13:1943-1954.
116. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
117. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070. Bapineuzumab 201 Clinical Trial Investigators.
118. Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., Sabbagh M., Honig L.S., Porsteinsson A.P., Ferris S., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N.Engl. J. Med. 2014, 370:322-333. Bapineuzumab 301 and 302 Clinical Trial Investigators.
119. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
120. Schneeberger A., Mandler M., Otawa O., Zauner W., Mattner F., Schmidt W. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J.Nutr. Health Aging 2009, 13:264-267.
121. Scholtzova H., Kascsak R.J., Bates K.A., Boutajangout A., Kerr D.J., Meeker H.C., Mehta P.D., Spinner D.S., Wisniewski T. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J.Neurosci. 2009, 29:1846-1854.
122. Scholtzova H., Chianchiano P., Pan J., Sun Y., Goñi F., Mehta P.D., Wisniewski T. Amyloid β and tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol. Commun. 2014, 2:101.
123. Schwartz M., Kipnis J., Rivest S., Prat A. How do immune cells support and shape the brain in health, disease, and aging?. J.Neurosci. 2013, 33:17587-17596.
124. Shankar G.M., Li S., Mehta T.H., Garcia-Muñoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
125. Shayan G., Adamiak B., Relkin N.R., Lee K.H. Longitudinal analysis of novel Alzheimer's disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. Electrophoresis 2012, 33:1975-1979.
126. Sigurdsson E.M. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J.Alzheimers Dis. 2008, 15:157-168.
127. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 2001, 159:439-447.
128. Sigurdsson E.M., Frangione B., Wisniewski T. Immunization for Alzheimer's disease. Drug Dev. Res. 2002, 56:135-142. 10.1002/ddr.10068.
129. Sigurdsson E.M., Knudsen E., Asuni A., Fitzer-Attas C., Sage D., Quartermain D., Goñi F., Frangione B., Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-β derivatives. J.Neurosci. 2004, 24:6277-6282.
130. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
131. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA 1997, 94:4109-4112.
132. Soscia S.J., Kirby J.E., Washicosky K.J., Tucker S.M., Ingelsson M., Hyman B., Burton M.A., Goldstein L.E., Duong S., Tanzi R.E., Moir R.D. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS ONE 2010, 5:e9505.
133. Sperling R., Salloway S., Brooks D.J., Tampieri D., Barakos J., Fox N.C., Raskind M., Sabbagh M., Honig L.S., Porsteinsson A.P., et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012, 11:241-249.
134. Streit W.J., Xue Q.S. Human CNS immune senescence and neurodegeneration. Curr. Opin. Immunol. 2014, 29:93-96.
135. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
136. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J.Neuropathol. Exp. Neurol. 1996, 55:1023-1025.
137. Vidal R., Frangione B., Rostagno A., Mead S., Révész T., Plant G., Ghiso J. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999, 399:776-781.
138. Vollmer J., Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61:195-204.
139. Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., Maguire R.P., Blennow K., Lundmark J., Staufenbiel M., et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012, 11:597-604.
140. Wingo T.S., Lah J.J., Levey A.I., Cutler D.J. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch. Neurol. 2012, 69:59-64.
141. Wisniewski T. Practice point commentary on "Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.". Nat. Clin. Pract. Neurol. 2005, 1:84-85.
142. Wisniewski T. Active immunotherapy for Alzheimer's disease. Lancet Neurol. 2012, 11:571-572.
143. Wisniewski T., Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol. 2005, 15:72-77.
144. Wisniewski T., Goñi F. Could immunomodulation be used to prevent prion diseases?. Expert Rev. Anti Infect. Ther. 2012, 10:307-317.
145. Wisniewski T., Goñi F. Immunotherapy for Alzheimer's disease. Biochem. Pharmacol. 2014, 88:499-507.
146. Wisniewski T., Sigurdsson E.M. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim. Biophys. Acta 2010, 1802:847-859.
147. Wisniewski H.M., Wegiel J. The role of microglia in amyloid fibril formation. Neuropathol. Appl. Neurobiol. 1994, 20:192-194.
148. Wisniewski H.M., Wegiel J., Wang K.C., Lach B. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. Acta Neuropathol. 1992, 84:117-127.
149. Wisniewski T., Prelli F., Scholtzova H., Chung E., Mehta P.D., Kascsak R., Kascsak R., Goñi F. Immunotherapy targeting abnormal protein conformation. Alzheimers Dement. 2009, 5:P113. 10.1016/j.jalz.2009.05.354.
150. Yanamandra K., Kfoury N., Jiang H., Mahan T.E., Ma S., Maloney S.E., Wozniak D.F., Diamond M.I., Holtzman D.M. Anti-tau antibodies that block tau aggregate seeding invitro markedly decrease pathology and improve cognition invivo. Neuron 2013, 80:402-414.
151. Yoshiyama Y., Lee V.M., Trojanowski J.Q. Therapeutic strategies for tau mediated neurodegeneration. J.Neurol. Neurosurg. Psychiatry 2013, 84:784-795.